

Drug Policy:

Fyarro™ (intravenous sirolimus)

POLICY NUMBER UM ONC_1457	SUBJECT Fyarro™ (intravenous sirolimus)		DEPT/PROGRAM UM Dept	PAGE 1 of 3
DATES COMMITTEE REVIEWED 01/12/22, 05/11/22, 01/11/23	APPROVAL DATE January 11, 2023	EFFECTIVE DATE January 27, 2023	COMMITTEE APPROVAL DATES 01/12/22, 05/11/22, 01/11/23	
PRIMARY BUSINESS OWNER: UM		COMMITTEE/BOARD APPROVAL Utilization Management Committee		
URAC STANDARDS HUM v8: UM 1-2; UM 2-1	NCQA STANDARDS UM 2		ADDITIONAL AREAS OF IMPACT	
CMS REQUIREMENTS	STATE/FEDERAL REQUIREMENTS		APPLICABLE LINES OF BUSINESS Commercial, Exchange, Medicaid	

I. PURPOSE

To define and describe the accepted indications for Fyarro (intravenous sirolimus) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

1. When health plan Medicaid coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)
2. When health plan Exchange coverage provisions-including any applicable PDLs (Preferred Drug Lists)-conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the [Preferred Drug Guidelines OR](#)

3. When Health Plans utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, and there is no Health Plan PDL applicable, the [Preferred Drug Guidelines](#) shall follow NCH recommended agents/regimens/preferred drugs **AND**
4. Continuation requests of previously approved, non-preferred medication are not subject to this provision **AND**
5. When applicable, generic alternatives are preferred over brand-name drugs **AND**
6. When there is a documented drug shortage, disease progression, contraindication, or confirmed intolerance to a preferred drug/regimen, per NCH Policy and Pathway, the available alternative product may be used if deemed medically appropriate and the indication is listed in a standard reference compendia or accepted peer review literature. For a list of current drug shortages, please refer to FDA drug shortage website in the reference section.

B. Perivascular Epithelioid Cell Tumor (PEComa, Angiomyolipoma or Lymphangioliomyomatosis)

1. **NOTE:** Per NCH policy, Fyarro (intravenous sirolimus) is non-preferred for the treatment of advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa, Angiomyolipoma, or Lymphangioliomyomatosis). This recommendation is based on the lack of Level 1 evidence (randomized trials and/or meta-analyses) to show superior outcomes with Fyarro (intravenous sirolimus) over Rapamune (oral sirolimus).
2. The member has locally advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa, Angiomyolipoma, or Lymphangioliomyomatosis) and Fyarro (intravenous sirolimus) will be used as monotherapy **AND** the member is unable to tolerate or has a contraindication to the oral formulation of sirolimus, Rapamune.

III. EXCLUSION CRITERIA

- A. Disease progression while taking Fyarro (intravenous sirolimus) or another MTOR inhibitor [e.g., Rapamune (oral sirolimus), Afinitor (everolimus), Torisel (temsirolimus)].
- B. Dosing exceeds single dose limit of Fyarro (intravenous sirolimus) 100 mg/m².
- C. Investigational use of Fyarro (intravenous sirolimus) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
 1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
 2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
 3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definition of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
 4. Whether the experimental design, in light of the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
 5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.

6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

IV. MEDICATION MANAGEMENT

- A. Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY

- A. Review – Utilization Management Department
- B. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

- A. None

VII. REFERENCES

- A. Wagner AJ, et al. Nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. *J Clin Oncol*. 2021 Nov 20;39(33):3660-3670.
- B. Fyarro prescribing information. Aadi Bioscience Inc., Pacific Palisades, CA 2022.
- C. Clinical Pharmacology Elsevier Gold Standard 2023.
- D. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, CO 2023.
- E. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2023.
- F. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs Bethesda, MD 2023.
- G. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
- H. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf>.
- I. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: <http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm>.
- J. NCQA UM 2023 Standards and Elements.